Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform

  • STAR Protoc. 2025 Dec 1;6(4):104250. doi: 10.1016/j.xpro.2025.104250.
Jung Sook Choi  1 ,  Min Sang Lee  2 ,  Myung Jin Song  1 ,  Kwiwan Jeong  3
Affiliations
  • 1. Bio Industry Department, Gyeonggido Business & Science Accelerator, Suwon 16229, Republic of Korea.
  • 2. Bio Industry Department, Gyeonggido Business & Science Accelerator, Suwon 16229, Republic of Korea. Electronic address: [email protected].
  • 3. Bio Industry Department, Gyeonggido Business & Science Accelerator, Suwon 16229, Republic of Korea. Electronic address: [email protected].
PMID: 41335519 DOI: 10.1016/j.xpro.2025.104250
Abstract

Tumor organoids provide physiologically relevant three-dimensional (3D) models that overcome the limitations of two-dimensional cultures in drug screening. Here, we present a protocol for generating compact and reproducible ovarian Cancer organoids using SKOV-3 cells embedded in growth-factor-reduced Matrigel and dispensed onto a 384-pillar plate. We describe automated cell-matrix dispensing, calcein-AM viability staining, and high-content fluorescence imaging for IC50 analysis. This protocol enables scalable, standardized, and high-throughput drug screening with tumor organoids for quantitative drug efficacy evaluation.

Keywords
Cancer; High-throughput screening; Organoids.
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10193
    AZD-1480
    99.74%, JAK1/2 Inhibitor
    target: JAK
    Research Areas: Cancer